Skin discoloration, skin & hair depigmentation & other dermatological effects. Discontinue if signs/symptoms of Stevens-Johnson or erythema multiforme (eg, progressive rash often w/ blisters/mucosal lesions) are present. Hemorrhagic events (GI, resp, tumor, urinary tract, brain, pulmonary). Not for patients w/ NSCLC. GI complications including GI perforation in patients w/ intra-abdominal malignancies. GI events (eg, nausea, diarrhea, stomatitis, dyspepsia & vomiting). Discontinue if symptoms of pancreatitis are present. Monitor liver function tests (ALT, AST, bilirubin levels) before initiation of therapy, during each cycle of therapy & as clinically indicated. Perform CBC at the beginning of each treatment cycle. Patients at risk or w/ history of heart failure, cardiomyopathy, myocardial ischemia & MI; QT interval prolongation, those taking antiarrhythmics or w/ relevant pre-existing cardiac disease, bradycardia or electrolyte disturbances. Discontinue if clinical manifestations of CHF are present. Temporary suspension in patients w/ severe HTN; seizures. Closely observe for signs & symptoms of thyroid dysfunction. Cases of impaired wound healing during therapy, temporary interruption is recommended in patients undergoing major surgical procedures. Avoid invasive dental procedures in patients who have previously or are receiving IV bisphosphonates. Those w/ high tumor burden prior to therapy is at risk of tumor lysis syndrome. Discontinue use if patients develop necrotizing fasciitis, thrombotic microangiopathy, nephrotic syndrome. Risk of hypoglycemia. May impair ability to drive or operate machinery. Women of childbearing potential. Impairment of fertility. Pregnancy & lactation. Childn.